1304 related articles for article (PubMed ID: 9662379)
1. Tissue microarrays for high-throughput molecular profiling of tumor specimens.
Kononen J; Bubendorf L; Kallioniemi A; Bärlund M; Schraml P; Leighton S; Torhorst J; Mihatsch MJ; Sauter G; Kallioniemi OP
Nat Med; 1998 Jul; 4(7):844-7. PubMed ID: 9662379
[TBL] [Abstract][Full Text] [Related]
2. Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression.
Wani G; Noyes I; Milo GE; D'Ambrosio SM
Mol Med; 1997 Apr; 3(4):273-83. PubMed ID: 9131589
[TBL] [Abstract][Full Text] [Related]
3. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer.
Zhang D; Salto-Tellez M; Putti TC; Do E; Koay ES
Mod Pathol; 2003 Jan; 16(1):79-84. PubMed ID: 12527717
[TBL] [Abstract][Full Text] [Related]
4. Microcysts and breast cancer: a study of biological markers in archival biopsy material.
Tran DD; Lawson JS
Breast Cancer Res Treat; 2002 Oct; 75(3):213-20. PubMed ID: 12353810
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
[TBL] [Abstract][Full Text] [Related]
6. Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy.
Bieche I; Parfait B; Le Doussal V; Olivi M; Rio MC; Lidereau R; Vidaud M
Cancer Res; 2001 Feb; 61(4):1652-8. PubMed ID: 11245479
[TBL] [Abstract][Full Text] [Related]
7. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
[TBL] [Abstract][Full Text] [Related]
8. Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor.
Yu J; Deshmukh H; Payton JE; Dunham C; Scheithauer BW; Tihan T; Prayson RA; Guha A; Bridge JA; Ferner RE; Lindberg GM; Gutmann RJ; Emnett RJ; Salavaggione L; Gutmann DH; Nagarajan R; Watson MA; Perry A
Clin Cancer Res; 2011 Apr; 17(7):1924-34. PubMed ID: 21325289
[TBL] [Abstract][Full Text] [Related]
9. Systematic functional perturbations uncover a prognostic genetic network driving human breast cancer.
Gallenne T; Ross KN; Visser NL; Salony ; Desmet CJ; Wittner BS; Wessels LFA; Ramaswamy S; Peeper DS
Oncotarget; 2017 Mar; 8(13):20572-20587. PubMed ID: 28411283
[TBL] [Abstract][Full Text] [Related]
10. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast.
Lebeau A; Unholzer A; Amann G; Kronawitter M; Bauerfeind I; Sendelhofert A; Iff A; Löhrs U
Breast Cancer Res Treat; 2003 May; 79(2):187-98. PubMed ID: 12825853
[TBL] [Abstract][Full Text] [Related]
11. Tissue microarrays for gene amplification surveys in many different tumor types.
Schraml P; Kononen J; Bubendorf L; Moch H; Bissig H; Nocito A; Mihatsch MJ; Kallioniemi OP; Sauter G
Clin Cancer Res; 1999 Aug; 5(8):1966-75. PubMed ID: 10473073
[TBL] [Abstract][Full Text] [Related]
12. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
[TBL] [Abstract][Full Text] [Related]
13. Tissue array for Tp53, C-myc, CCND1 gene over-expression in different tumors.
Liu GY; Luo Q; Xiong B; Pan C; Yin P; Liao HF; Zhuang WC; Gao HZ
World J Gastroenterol; 2008 Dec; 14(47):7199-207. PubMed ID: 19084934
[TBL] [Abstract][Full Text] [Related]
14. Significance of HER2 and C-MYC oncogene amplifications in breast cancer in atomic bomb survivors: associations with radiation exposure and histologic grade.
Miura S; Nakashima M; Ito M; Kondo H; Meirmanov S; Hayashi T; Soda M; Matsuo T; Sekine I
Cancer; 2008 May; 112(10):2143-51. PubMed ID: 18348306
[TBL] [Abstract][Full Text] [Related]
15. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
16. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
17. Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer.
Grob TJ; Heilenkötter U; Geist S; Paluchowski P; Wilke C; Jaenicke F; Quaas A; Wilczak W; Choschzick M; Sauter G; Lebeau A
Breast Cancer Res Treat; 2012 Jul; 134(2):561-7. PubMed ID: 22610646
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclooxygenase-2 (COX-2) and p53 in neighboring invasive and in situ components of breast tumors.
Serra KP; Sarian LO; Rodrigues-Peres RM; Vassallo J; Soares FA; Pinto GA; da Cunha IW; Shinzato JY; Derchain SF
Acta Histochem; 2012 May; 114(3):226-31. PubMed ID: 21683430
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
20. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
